Changes in characteristics of patients with hepatitis C virus-related cirrhosis from the beginning of the interferon-free era

Table 6 Logistic multiple regression results on association between selected parameters significant in univariate analysis and non-response to antiviral treatment

Parameter	OR	95%CI	P value
Age ≥ 75 yr	0.81	0.38-1.72	0.5915
Obesity (BMI ≥ 30 kg/m2)	1.15	0.80-1.66	0.4473
Male gender	2.28	1.57-3.29	< 0.0001
Platelets < 100000/μL	1.37	0.98-1.93	0.0694
GT1b	1.54	0.66-3.59	0.3145
GT3	6.40	2.69-15.22	< 0.0001
Bilirubin > 3 mg/dL	0.29	0.08-1.00	0.0506
Albumin < 2.8 g/dL	0.98	0.44-2.20	0.966
Documented esophageal varices	1.43	1.00-2.06	0.052
Hepatic decompensation at baseline	1.49	0.76-2.91	0.2496
Hypertension	0.93	0.67-1.30	0.6783
Child-Pugh, B or C	1.80	0.95-3.42	0.0716
SOF/(VEL ± RBV)	1.13	0.76-1.69	0.541
GZR/(EBR ± RBV)	0.91	0.46-1.80	0.7951
OBV/PTV/(r ± DSV ± RBV)	0.58	0.35-0.95	0.0319
Treatment experienced	1.66	1.18-2.33	0.0039

OR: Odds ratio; CI: Confidence interval; BMI: Body mass index; GT: Genotype; SOF: Sofosbuvir; VEL: Velpatasvir; RBV: Ribavirin; GZR: Grazoprevir; EBR: Elbasvir; OBV: Ombitasvir; PTV/r: Paritaprevir; DSV: Dasabuvir.